Publication: Conjunctival papilloma treatment outcomes: a 12-year-retrospective study
0
0
Issued Date
2023
Resource Type
File Type
application/pdf
Rights Holder(s)
Scopus
Bibliographic Citation
Eye (Basingstoke). Vol 37, No.5 (2023), p.977-982
Suggested Citation
Sripawadkul W., Theotoka D., Zein M., Galor A., Karp C.L. Conjunctival papilloma treatment outcomes: a 12-year-retrospective study. Eye (Basingstoke). Vol 37, No.5 (2023), p.977-982. doi:10.1038/s41433-022-02329-3 Retrieved from: https://hdl.handle.net/20.500.14740/12668
Author(s)
Other Contributor(s)
Abstract
Background: Conjunctival papilloma is often resistant to treatment. Various therapies have been reported with no gold standard. The purpose of this study was to compare treatment outcomes after various therapies. Methods: A retrospective chart review of 30 conjunctival papilloma patients from 2009–2020. Data on demographics, tumour characteristics, primary treatment and outcomes were collected. The primary outcome was the frequency of complete tumour resolution and recurrence rate of each primary therapy. The secondary outcome was treatment related side effects. Results: The mean age was 57.5 years (3–93 years) with male predominance (n = 22, 73.3%). Eleven eyes were treated with interferon α-2b (IFN), seven with 5-fluorouracil (5FU), and 10 with excision biopsy and cryotherapy (6 with adjuvant therapy with IFN). The frequency of tumour resolution was 36.4% (4/11), 28.5% (2/7), and 100% (10/10) in each group, respectively. The mean time to resolution was faster in the surgical group compared to the medical group (1 day vs 159 days, p < 0.001). There was higher tumour recurrence with 11% in the surgical vs 0% in the medical group at 6 months and at 12 months, 22% recurrence in the surgical and 0% in the medical group (p = 0.52). However, the differences were not statistically significant. Conclusion: Papilloma resolution is faster with surgical excision as compared to medical therapy. However, recurrences are more frequent after surgical versus medical treatment. © 2022, The Author(s), under exclusive licence to The Royal College of Ophthalmologists.